A comprehensive view of sanofi sa. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi reports Q1 business net income of €2.42B, up 16% from a year ago, with sales up 12.6% year-over-year to €9.67B driven by 54.2% growth in Dupixent dupilumab sales, cough/pain medicine growth; polio, pertussis, hib vaccines also show strong sales
Published: May 02, 2022 by SeeNews Pharmaceuticals
Sanofi completes tests on first influenza vaccine 100% formulated, filled, bottled, packaged at Ocoyoaca and Cuautitlán Izcalli, Mexico, facilities; Sanofi has invested US$12M to develop specialty pharmaceutical products, medicines, vaccines in Mexico
Published: May 02, 2022 by CE Noticias Financieras
Sanofi Consumo plant in Ocoyoacac, Mexico, makes 100 million solid, liquid OTC drug packets for local market, 20 million units for other markets, accounting for 40% of Sanofi’s international production; 100-thousand-square-meter plant has 274 employees
Published: April 12, 2022 by CE Noticias Financieras
FDA accepts priority review of Regeneron, Sanofi’s sBLA for injectable Dupixent dupilumab 300 mg weekly to treat eosinophilic esophagitis in adult, pediatric patients aged 12 years and older; 160,000 patients in US are currently treated for EoE
Published: April 06, 2022 by Regeneron Pharmaceuticals Inc.
Sanofi Canada announces expanded approval in Canada of Dupixent dupilumab injection for severe asthma patients aged six to 11 years with type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma; 15%-to-25% of Canadian kids have asthma
Published: March 31, 2022 by Canada Newswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count